Test Price
2,800 AED✅ Home Collection Available
AARS1 Gene Early Infantile Epileptic Encephalopathy Type 29 Genetic Test in UAE
Executive Summary & Core Metrics
This state-of-the-art NGS test delivers definitive diagnosis for AARS1-related early infantile epileptic encephalopathy (EIEE29) with 99.9% diagnostic sensitivity under ISO 9001:2015 certified protocols. We provide hospital-grade home collection via cold-chain logistics (8 AM–11 PM), telephonic post-test clinical guidance, and direct insurance billing verification on WhatsApp.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Certified Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM–11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Price: 2800 AED | Turnaround Time: 3–4 Weeks
Test Overview & Methodology
The AARS1 Gene NGS Test identifies pathogenic variants linked to Early Infantile Epileptic Encephalopathy Type 29, a severe neurodevelopmental disorder starting in infancy. This comprehensive assay analyses the entire coding region of the AARS1 gene using high-depth next‑generation sequencing with Sanger confirmation of all detected variants, enabling precise clinical diagnosis and informed family planning.
| Parameter | Our Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity for AARS1 variants | ~95% (lower depth for single gene) |
| Methodology | NGS + Sanger confirmation | NGS only; often requires secondary confirmation |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Interpretation | Dedicated genetic counsellor report | Broad report with incidental findings |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I understand the overwhelming journey families face when a child presents with early-onset seizures. This test provides a definitive molecular answer, but it must be integrated with a full clinical evaluation. I encourage parents to discuss results comprehensively with their neurologist or geneticist, as not all variants lead to the same disease severity.”
— Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue or adjust any prescribed antiepileptic medication without consulting your treating physician. Abrupt changes may precipitate life-threatening seizure exacerbation.
Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not indicated for asymptomatic adults without a family history; it requires pre-test genetic counselling and a suspected clinical phenotype. Minors must have legal guardian consent per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- ER Red Flags: Prolonged seizure (>5 minutes), respiratory distress, cyanosis, or altered consciousness require immediate emergency care — dial 998.
- Post-Test: Do not interpret results in isolation. Contact our helpline for clinical correlation.
Patient FAQ & Clinical Guidance
1. How accurate is the AARS1 NGS test for diagnosing early infantile epileptic encephalopathy type 29?
Our assay achieves 99.9% diagnostic sensitivity by combining high-depth next-generation sequencing with Sanger confirmation of all detected variants, ensuring no pathogenic mutation is missed.
2. Is home sample collection available and how is the sample handled?
Yes, our licensed phlebotomists perform hospital-grade venous blood collection at your doorstep between 8 AM and 11 PM, using a validated cold-chain system to preserve DNA integrity during transport.
3. What do I need to prepare before the test?
A pre-genetic counselling session is mandatory to draw a detailed pedigree chart of family members affected by AARS1-related conditions. Provide the completed clinical history questionnaire and list all medications to your counsellor.
4. What is the typical turnaround time for results?
Results are available within 3–4 weeks from sample receipt. You will receive a detailed genetic report with interpretation and a telephonic follow-up.
UAE Regulatory & Data Privacy Adherence
Compliance with UAE Law
DNA Labs UAE operates under DHA Facility License No. 1143 and adheres to the Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is handled with strict confidentiality, encrypted storage, and access controls. Your consent is obtained prior to any testing, and results are shared only with authorized healthcare providers and legal guardians as required.
Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | AARS1 Gene Early Infantile Epileptic Encephalopathy Type 29 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA tube) |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | G40.4 (Epileptic encephalopathy) |
| LOINC Code | 82930-0 (DNA sequence analysis by NGS) |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians